BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SMP3124LP readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SMP3124LP\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06526819-2733@assetmemo.bio
DTSTAMP:20261121T005427Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:SMP3124LP: Phase 1/2 readout est. (NCT06526819)
DESCRIPTION:SMP3124LP\, phase 1/2.\nStudy: SMP-3124LP in Adults With Advanc
 ed Solid Tumors\nEstimated primary completion: December 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/smp3124lp#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06526819
URL:https://assetmemo.bio/drug/smp3124lp#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
